





# HPV Vaccine Quality Improvement Study Quarterly Data & Feedback Report

| Practice ID:         | 6                 |                    |             |
|----------------------|-------------------|--------------------|-------------|
| Baseline Period:     | Feb 2017-Jan 2018 | Date of Data Pull: | 2/28/2020   |
| MOC Project Periods: | Feb 2018-Jan 2019 | Data through:      | 2020 Week 7 |

This Data and Feedback Report complements the weekly run chart data reports you receive from VHealth.

In this report, we present your data in the form of control charts, which allow us to apply some statistical rules to determine whether or not movements in the data over time represent real shifts in the outcome measures, rather than just random variation.

We have included a written summary interpreting each measure for you -- what we see, what it could mean, and recommended actions for your consideration.

## **Data Summary & Feedback**

## **Report Period: November - January 2020**

1st MOC Project Change Options: A-Bundle 3 Adolescent Vaccines, B-Patient Education Materials
2nd MOC Project Change Options: E-Reminder/Recall for Vaccines, I-Standing Orders for 1st Dose of Vaccines

| Summary Measure #1: 1+ Dose (Initiation) Among en       | ntire active patient population                     |  |
|---|---|--|
| What we see   | What it could mean                                  | Recommended actions                                  |
| Baseline and all quarters through Y2Q4 rates for ages   | Although your rates are below both the US and TN,   | Continue to include data review as a standing        |
| 13-17 are below TN and US. Note: both the TN and        | your practice is making good progress in initiating | agenda item in meetings. As necessary, remind        |
| US rates for 2018 are higher than the 2017 rates.       | the vaccine.  | providers and staff of the adopted workflows to      |
|   |   | continue your improvement trend.                     |
| For ages 11-17, there is a 14.6 percentage point        | There is good progress in dose initiation           | Continue to monitor over time to hold your gains     |
| increase from baseline to end of Y2Q4. For ages 13-     | percentages. Your efforts are having a positive     | and continue to improve.                             |
| 17, an increase of 13.8 percentage points.              | impact.   |  |
| Summary Measure #2: All Doses (Complete) Among          | entire active patient population                    |  |
| What we see   | What it could mean                                  | Recommended actions                                  |
| Baseline and all quarter rates through Y2Q4 for ages    | Although your rates are below both the US and TN,   | Review best practices for HPV vaccine                |
| 13-17 are below TN and US. <i>Note: both the TN and</i> | your practice is making progress in completing the  | communication with all providers, including          |
| US rates for 2018 are higher than the 2017 rates.       | vaccine series.                                     | communication strategies for hesitant parents.       |
|   |   |  |
| For ages 11-17, there is a 11.4 percentage point        | There is good progress in completion rates, but     | Continue to monitor over time to hold your gains     |
| increase from baseline to end of Y2Q4. For ages 13-     | additional increases are needed for it to be a      | and continue to improve.                             |
| 17, an increase of 12.9 percentage points.              | significant improvement.                            |  |
| Weekly Measure #1: HPV Dose Due (Well)                  |   |  |
| WELL visits with patients up-to-date for HPV vaccine (  | % of visits with HPV due, ages 11-17)               |  |
| What we see   | What it could mean                                  | Recommended actions                                  |
| Baseline mean (average) remains at 47% through          | Implementation of standing orders for 1st dose,     | Review workflow for standing orders and discuss any  |
| January 2020.   | integrating patient education materials, and parent | obstacles that may exist. Revise adopted workflow a  |
|   | reminders for vaccines are not showing an impact on | 1  |
|   | this measure.                                       | education and reminders for due/overdue vaccines.    |
| Weekly Measure #2: HPV Dose Due (Non-Well)              |   |  |
| NON-WELL visits with patients up-to-date for HPV vac    | ccine (% of visits with HPV due, ages 11-17)        |  |
| What we see   | What it could mean                                  | Recommended actions                                  |
| Baseline mean (average) of 2% dropped to less than      | Your practice did not choose this as one of your    | Consider offering the HPV vaccine during non-well    |
| 1% in August and remains the same through January       | change options, so no change was expected.          | visits on a regular basis as an option for providing |
| 2020.   |   | greater coverage.                                    |

## **Data Summary & Feedback**

#### **Report Period: November - January 2020**

| Weekl   | / Measure    | #3· HPV   | Dose | Due | (ΙΙΔ) |
|---------|--------------|-----------|------|-----|-------|
| IVVECKI | / IVICasul C | MJ. HIF V | DUSE | Duc | (AII) |

ALL visits with patients up-to-date for HPV vaccine (% of visits with HPV due, ages 11-17)

| What we see                                       | What it could mean                               | Recommended actions            |
|---|--|--------------------------------|
| The mean remains at 13% through January 2020.     | More visits during the summer months is a common | Continue to monitor over time. |
| There are several weeks above the mean during the | seasonal pattern.                                |                                |
| summer months. This measure is a combination of   |  |                                |
| Measures #1 and #2.                               |  |                                |

#### Weekly Measure #4: HPV Recommend-Well

WELL visits with documented provider recommendation (given or refused) (% of visits with HPV due, ages 11-17)

| What we see  | What it could mean                                 | Recommended actions                                   |
|--|--|---|
| This measure shows provider recommendation in        | The difference between this measure and measure    | Discuss with your team where and how they are         |
| well visits, counted as vaccines given plus vaccines | #1 shows documented patient refusal of HPV vaccine | documenting refusals for well visits. Review "dummy   |
| refused (if documented). The mean remains at 50%     | in 3% of well visits.                              | refusal codes." If needed, submit a technical         |
| through January 2020.                                |  | assistance ticket to VHealth to determine if they are |
|  |  | capturing documented refusals.                        |
|  |  |   |

#### Weekly Measure #5: HPV Recommend-All

ALL visits with documented provider recommendation (given or refused) (% of visits with HPV due, ages 11-17)

| What we see   | What it could mean                                   | Recommended actions                                    |
|---|--|--|
| This measure shows provider recommendation in       | The difference between this measure and measure      | Discuss with your team where and how they are          |
| ALL visits, counted as vaccines given plus vaccines | #3 shows a few documented patient refusals of HPV    | documenting refusals for well and non-well visits.     |
| refused (if documented). The mean increased during  | vaccine in all visits. More visits during the summer | Review "dummy refusal codes." If needed, submit a      |
| the spring/summer months, dropped to 13% in         | months is a common seasonal pattern.                 | technical assistance ticket to VHealth to determine if |
| August, and remains at 13% through January 2020.    |  | they are capturing documented refusals.                |
|   |  |  |


#### Weekly Measure #6: Bundle Adol Vax

Visits for ages 11-12 year-olds in which HPV & meningococcal vaccines are bundled with Tdap, when due (% of visits, ages 11-12)

| What we see                                       | What it could mean                                 | Recommended actions                                 |
|---|--|---|
| The mean remains at 68% through January 2020 with | Implementation of vaccine communication            | Share the data with providers. Discuss obstacles to |
| a drop to 20% in January.                         | strategies, bundling, and use of patient education | bundling for all 11-12 year old visits and identify |
|   | materials appears to have resulted in a sustained  | ways to minimize or eliminate them. Review use of   |
|   | improvement in bundled adolescent vaccines since   | patient education materials, including hesitant     |
|   | baseline. Additional opportunity to improve.       | parent materials.                                   |
|   |  |   |

#### **Summary Measure: 1+ Dose (Initiation)**

Note: US and TN data were updated for 2018




Notes: Rates are for males and females combined.

Practice rates calculated on all active patients (at least one visit in past three years), ages 11-17 or ages 13-17, as indicated.

|            |     | Baseline | •   |     | Fi    | irst MO | C Proje | ct    |     |     | Sec   | ond M | OC Proj | ect   |     |     |       |     |     | М     | aintan | ce Perio | od    |     |     |       |     |
|------------|-----|----------|-----|-----|-------|---------|---------|-------|-----|-----|-------|-------|---------|-------|-----|-----|-------|-----|-----|-------|--------|----------|-------|-----|-----|-------|-----|
|            |     | ec 201   | 7   |     | Y1Q1  |         |         | Y1Q2  |     |     | Y1Q3  |       |         | Y1Q4  |     |     | Y2Q1  |     |     | Y2Q2  |        |          | Y2Q3  |     |     | Y2Q4  |     |
|            | #   | Total    | %   | #   | Total | %       | #       | Total | %   | #   | Total | %     | #       | Total | %   | #   | Total | %   | #   | Total | %      | #        | Total | %   | #   | Total | %   |
| Ages 11-17 | 538 | 2035     | 26% | 568 | 2012  | 28%     | 641     | 1985  | 32% | 689 | 1954  | 35%   | 722     | 1961  | 37% | 747 | 1999  | 37% | 804 | 2044  | 39%    | 838      | 2037  | 41% | 850 | 2074  | 41% |
| Ages 13-17 | 488 | 1533     | 32% | 501 | 1501  | 33%     | 528     | 1474  | 36% | 560 | 1447  | 39%   | 591     | 1445  | 41% | 612 | 1467  | 42% | 644 | 1492  | 43%    | 673      | 1506  | 45% | 707 | 1550  | 46% |

## Summary Measure: All Doses (Complete) Note: US and TN data were updated for 2018




Notes: Rates are for males and females combined.

Practice rates calculated on all active patients (at least one visit in past three years), ages 11-17 or ages 13-17, as indicated.

|            | ı   | Baseline | 9   |     | Fi    | rst MO | C Proje | ct    |     |     | Sec   | ond M | OC Pro | ject  |     |     |       |     |     | М     | aintan | ce Perio | od    |     |     |       |     |
|------------|-----|----------|-----|-----|-------|--------|---------|-------|-----|-----|-------|-------|--------|-------|-----|-----|-------|-----|-----|-------|--------|----------|-------|-----|-----|-------|-----|
|            | D   | ec 201   | 7   |     | Y1Q1  |        |         | Y1Q2  |     |     | Y1Q3  |       |        | Y1Q4  |     |     | Y2Q1  |     |     | Y2Q2  |        |          | Y2Q3  |     |     | Y2Q4  |     |
|            | #   | Total    | %   | #   | Total | %      | #       | Total | %   | #   | Total | %     | #      | Total | %   | #   | Total | %   | #   | Total | %      | #        | Total | %   | #   | Total | %   |
| Ages 11-17 | 280 | 2035     | 14% | 288 | 2012  | 14%    | 317     | 1985  | 16% | 347 | 1954  | 18%   | 379    | 1961  | 19% | 401 | 1999  | 20% | 465 | 2044  | 23%    | 500      | 2037  | 25% | 522 | 2074  | 25% |
| Ages 13-17 | 270 | 1533     | 18% | 280 | 1501  | 19%    | 306     | 1474  | 21% | 332 | 1447  | 23%   | 352    | 1445  | 24% | 366 | 1467  | 25% | 418 | 1492  | 28%    | 446      | 1506  | 30% | 472 | 1550  | 30% |


Measure: HPV 1+ Dose 11-17 yo

Description: Ranking of HPV vaccine initiation of all active patients ages 11-17 (%) among study sites



Measure: HPV 1+ Dose 13-17 yo

Description: Ranking of HPV vaccine initiation of all active patients ages 13-17 (%) among study sites



Your practice ranked **23rd** in **initiating** the HPV vaccine series among patients ages 13-17.

Baseline: 32.2% (Jan

2018).

**End of 12 months:** 40.9%


(Jan 2019).

Improvement: 8.7

percentage point increase in 12 months.

Measure: HPV Complete 11-17 yo

Description: Ranking of HPV vaccine completion of all active patients ages 11-17 (%) among study sites



Your practice ranked **22nd** in **completing** the HPV vaccine series among patients ages 11-17.

Baseline: 13.9% (Jan

2018).

**End of 12 months:** 19.3%


(Jan 2019).

**Improvement:** 5.4 percentage point increase

in 12 months.

Measure: HPV Complete 13-17 yo

Description: Ranking of HPV vaccine completion of all active patients ages 13-17 (%) among study sites



Your practice ranked **21st** in **completing** the HPV vaccine series among patients ages 13-17.

Baseline: 17.8% (Jan

2018).


**End of 12 months: 24.4%** 

(Jan 2019).

**Improvement:** 6.6 percentage point increase in 12 months.

Name: HPV Dose Due (Well)

**Description:** WELL visits with patients up-to-date for HPV vaccine (% of visits with HPV due, ages 11-17)




|      |          | Jan |     |     |     | Feb |     |      |     | Mar |     |     |     |     | Apr |     |     |     | May |     |     |     |     | Jun |     |     | 1   |
|------|----------|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|      | Week     | 1   | 2   | 3   | 4   | 5   | 6   | 7    | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | 19  | 20  | 21  | 22  | 23  | 24  | 25  | 26  |
| 2017 | Complete | 4   | 2   | 0   | 1   | 0   | 1   | 1    | 2   | 1   | 4   | 3   | 4   | 3   | 1   | 6   | 2   | 4   | 8   | 8   | 5   | 8   | 9   | 6   | 9   | 2   | 4   |
|      | Total    | 10  | 6   | 10  | 5   | 5   | 6   | 3    | 11  | 6   | 12  | 8   | 13  | 10  | 8   | 15  | 17  | 14  | 24  | 14  | 16  | 29  | 27  | 21  | 24  | 22  | 18  |
|      | Percent  | 40% | 33% | 0%  | 20% | 0%  | 17% | 33%  | 18% | 17% | 33% | 38% | 31% | 30% | 13% | 40% | 12% | 29% | 33% | 57% | 31% | 28% | 33% | 29% | 38% | 9%  | 22% |
| 2018 | Complete | 1   | 1   | 3   | 6   | 3   | 7   | 1    | 3   | 4   | 5   | 2   | 1   | 5   | 3   | 5   | 9   | 3   | 6   | 12  | 5   | 9   | 10  | 12  | 4   | 12  | 18  |
|      | Total    | 9   | 5   | 8   | 9   | 9   | 9   | 1    | 7   | 8   | 7   | 12  | 5   | 11  | 10  | 7   | 12  | 10  | 11  | 18  | 11  | 16  | 28  | 26  | 15  | 28  | 41  |
|      | Percent  | 11% | 20% | 38% | 67% | 33% | 78% | 100% | 43% | 50% | 71% | 17% | 20% | 45% | 30% | 71% | 75% | 30% | 55% | 67% | 45% | 56% | 36% | 46% | 27% | 43% | 44% |
| 2019 | Complete | 1   | 2   | 5   | 6   | 5   | 2   | 6    | 2   | 8   | 4   | 1   | 5   | 2   | 3   | 2   | 5   | 6   | 6   | 4   | 3   | 1   | 10  | 9   | 9   | 9   | 12  |
|      | Total    | 3   | 7   | 10  | 12  | 10  | 7   | 8    | 8   | 10  | 10  | 4   | 11  | 7   | 4   | 6   | 9   | 8   | 11  | 7   | 5   | 11  | 20  | 21  | 22  | 17  | 26  |
|      | Percent  | 33% | 29% | 50% | 50% | 50% | 29% | 75%  | 25% | 80% | 40% | 25% | 45% | 29% | 75% | 33% | 56% | 75% | 55% | 57% | 60% | 9%  | 50% | 43% | 41% | 53% | 46% |
| 2020 | Complete | 2   | 0   | 2   | 4   |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 1   |
|      | Total    | 5   | 4   | 6   | 9   |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 1   |
|      | Percent  | 40% | 0%  | 33% | 44% |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 1   |

|      |          | Jul |     |     |     | Aug |     |     |     |     | Sep |     |     |     | Oct |     |     |     | Nov  |      |      |     |      | Dec |     |     |     |
|------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|-----|------|-----|-----|-----|-----|
|      | Week     | 27  | 28  | 29  | 30  | 31  | 32  | 33  | 34  | 35  | 36  | 37  | 38  | 39  | 40  | 41  | 42  | 43  | 44   | 45   | 46   | 47  | 48   | 49  | 50  | 51  | 52  |
| 2017 | Complete | 10  | 6   | 11  | 23  | 9   | 13  | 5   | 3   | 3   | 6   | 3   | 4   | 3   | 0   | 1   | 2   | 4   | 2    | 0    | 3    | 2   | 1    | 1   | 3   | 5   | 2   |
|      | Total    | 24  | 27  | 33  | 52  | 34  | 29  | 15  | 15  | 17  | 15  | 10  | 18  | 13  | 7   | 12  | 7   | 6   | 5    | 4    | 10   | 14  | 6    | 9   | 6   | 8   | 6   |
|      | Percent  | 42% | 22% | 33% | 44% | 26% | 45% | 33% | 20% | 18% | 40% | 30% | 22% | 23% | 0%  | 8%  | 29% | 67% | 40%  | 0%   | 30%  | 14% | 17%  | 11% | 50% | 63% | 33% |
| 2018 | Complete | 8   | 11  | 14  | 15  | 30  | 17  | 3   | 6   | 7   | 5   | 2   | 6   | 9   | 10  | 3   | 3   | 2   | 3    | 3    | 2    | 7   | 4    | 5   | 1   | 1   | 2   |
|      | Total    | 15  | 22  | 31  | 44  | 64  | 40  | 6   | 14  | 12  | 9   | 12  | 18  | 20  | 14  | 11  | 7   | 4   | 3    | 7    | 2    | 12  | 4    | 10  | 6   | 5   | 3   |
|      | Percent  | 53% | 50% | 45% | 34% | 47% | 43% | 50% | 43% | 58% | 56% | 17% | 33% | 45% | 71% | 27% | 43% | 50% | 100% | 43%  | 100% | 58% | 100% | 50% | 17% | 20% | 67% |
| 2019 | Complete | 13  | 5   | 17  | 15  | 19  | 21  | 3   | 5   | 4   | 2   | 3   | 2   | 7   | 3   | 0   | 2   | 1   | 2    | 3    | 1    | 7   | 12   | 6   | 1   | 8   | 0   |
|      | Total    | 25  | 15  | 36  | 34  | 28  | 46  | 6   | 12  | 12  | 3   | 9   | 6   | 13  | 11  | 2   | 10  | 6   | 9    | 3    | 3    | 10  | 19   | 11  | 3   | 15  | 1   |
|      | Percent  | 52% | 33% | 47% | 44% | 68% | 46% | 50% | 42% | 33% | 67% | 33% | 33% | 54% | 27% | 0%  | 20% | 17% | 22%  | 100% | 33%  | 70% | 63%  | 55% | 33% | 53% | 0%  |

Name: HPV Dose (Non-Well)

**Description:** NON-WELL clinic visits with patients up-to-date for HPV vaccine (% of visits with HPV due, ages 11-17)




|      |          | Jan |    |    |    | Feb |    |    |    | Mar |    |    |    |     | Apr |    |    |    | May |     |     |    |     | Jun |     |     |     |
|------|----------|-----|----|----|----|-----|----|----|----|-----|----|----|----|-----|-----|----|----|----|-----|-----|-----|----|-----|-----|-----|-----|-----|
|      | Week     | 1   | 2  | 3  | 4  | 5   | 6  | 7  | 8  | 9   | 10 | 11 | 12 | 13  | 14  | 15 | 16 | 17 | 18  | 19  | 20  | 21 | 22  | 23  | 24  | 25  | 26  |
| 2017 | Complete | 0   | 0  | 0  | 0  | 1   | 1  | 0  | 2  | 0   | 0  | 1  | 0  | 0   | 0   | 0  | 0  | 1  | 0   | 3   | 4   | 0  | 2   | 1   | 0   | 0   | 0   |
|      | Total    | 21  | 30 | 33 | 27 | 39  | 53 | 49 | 45 | 32  | 42 | 43 | 22 | 29  | 29  | 30 | 34 | 29 | 40  | 31  | 26  | 19 | 18  | 27  | 37  | 25  | 16  |
|      | Percent  | 0%  | 0% | 0% | 0% | 3%  | 2% | 0% | 4% | 0%  | 0% | 2% | 0% | 0%  | 0%  | 0% | 0% | 3% | 0%  | 10% | 15% | 0% | 11% | 4%  | 0%  | 0%  | 0%  |
| 2018 | Complete | 0   | 0  | 1  | 1  | 0   | 1  | 0  | 1  | 0   | 0  | 3  | 1  | 2   | 1   | 0  | 1  | 1  | 1   | 1   | 1   | 0  | 0   | 1   | 0   | 0   | 2   |
|      | Total    | 17  | 36 | 27 | 32 | 52  | 68 | 69 | 43 | 32  | 40 | 36 | 24 | 13  | 27  | 34 | 40 | 25 | 33  | 24  | 26  | 26 | 13  | 26  | 22  | 20  | 12  |
|      | Percent  | 0%  | 0% | 4% | 3% | 0%  | 1% | 0% | 2% | 0%  | 0% | 8% | 4% | 15% | 4%  | 0% | 3% | 4% | 3%  | 4%  | 4%  | 0% | 0%  | 4%  | 0%  | 0%  | 17% |
| 2019 | Complete | 1   | 2  | 2  | 1  | 1   | 0  | 1  | 1  | 0   | 3  | 1  | 0  | 0   | 1   | 1  | 0  | 1  | 1   | 1   | 0   | 0  | 0   | 1   | 2   | 3   | 0   |
|      | Total    | 11  | 36 | 32 | 42 | 36  | 47 | 41 | 41 | 34  | 48 | 37 | 21 | 26  | 27  | 18 | 24 | 23 | 35  | 22  | 20  | 17 | 24  | 20  | 18  | 24  | 18  |
|      | Percent  | 9%  | 6% | 6% | 2% | 3%  | 0% | 2% | 2% | 0%  | 6% | 3% | 0% | 0%  | 4%  | 6% | 0% | 4% | 3%  | 5%  | 0%  | 0% | 0%  | 5%  | 11% | 13% | 0%  |
| 2020 | Complete | 1   | 1  | 0  | 0  |     |    |    |    |     |    |    |    |     |     |    |    |    |     |     |     |    |     |     |     |     |     |
|      | Total    | 20  | 39 | 31 | 35 |     |    |    |    |     |    |    |    |     |     |    |    |    |     |     |     |    |     |     |     |     |     |
|      | Percent  | 5%  | 3% | 0% | 0% |     |    |    |    |     |    |    |    |     |     |    |    |    |     |     |     |    |     |     |     |     |     |

|      |          | Jul |    |    |    | Aug |    |     |    |    | Sep |    |    |    | Oct |    |    |    | Nov |    |    |    |    | Dec |    |    |    |
|------|----------|-----|----|----|----|-----|----|-----|----|----|-----|----|----|----|-----|----|----|----|-----|----|----|----|----|-----|----|----|----|
|      | Week     | 27  | 28 | 29 | 30 | 31  | 32 | 33  | 34 | 35 | 36  | 37 | 38 | 39 | 40  | 41 | 42 | 43 | 44  | 45 | 46 | 47 | 48 | 49  | 50 | 51 | 52 |
| 2017 | Complete | 0   | 1  | 1  | 1  | 1   | 0  | 0   | 1  | 1  | 0   | 0  | 1  | 0  | 0   | 0  | 0  | 0  | 0   | 0  | 1  | 1  | 0  | 3   | 0  | 0  | 0  |
|      | Total    | 12  | 29 | 24 | 36 | 29  | 28 | 25  | 30 | 30 | 29  | 23 | 42 | 42 | 35  | 25 | 31 | 33 | 27  | 33 | 24 | 25 | 43 | 39  | 55 | 37 | 17 |
|      | Percent  | 0%  | 3% | 4% | 3% | 3%  | 0% | 0%  | 3% | 3% | 0%  | 0% | 2% | 0% | 0%  | 0% | 0% | 0% | 0%  | 0% | 4% | 4% | 0% | 8%  | 0% | 0% | 0% |
| 2018 | Complete | 0   | 1  | 0  | 1  | 1   | 1  | 3   | 0  | 2  | 0   | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 2   | 1  | 2  | 1  | 0  | 0   | 1  | 0  | 1  |
|      | Total    | 13  | 16 | 27 | 21 | 17  | 24 | 19  | 19 | 24 | 22  | 23 | 24 | 28 | 35  | 38 | 25 | 22 | 36  | 37 | 34 | 16 | 24 | 40  | 31 | 32 | 12 |
|      | Percent  | 0%  | 6% | 0% | 5% | 6%  | 4% | 16% | 0% | 8% | 0%  | 0% | 0% | 0% | 0%  | 0% | 0% | 0% | 6%  | 3% | 6% | 6% | 0% | 0%  | 3% | 0% | 8% |
| 2019 | Complete | 0   | 0  | 2  | 1  | 3   | 0  | 0   | 1  | 1  | 0   | 1  | 0  | 1  | 0   | 0  | 0  | 0  | 0   | 0  | 0  | 0  | 0  | 0   | 0  | 0  | 0  |
|      | Total    | 13  | 24 | 25 | 17 | 31  | 27 | 24  | 28 | 32 | 27  | 34 | 17 | 26 | 22  | 20 | 17 | 27 | 22  | 33 | 35 | 39 | 10 | 18  | 35 | 30 | 15 |
|      | Percent  | 0%  | 0% | 8% | 6% | 10% | 0% | 0%  | 4% | 3% | 0%  | 3% | 0% | 4% | 0%  | 0% | 0% | 0% | 0%  | 0% | 0% | 0% | 0% | 0%  | 0% | 0% | 0% |

Name: HPV Dose Due (All)

**Description:** ALL visits with patients up-to-date for HPV vaccine (% of visits with HPV due, ages 11-17)




|      |          | Jan |    |     |     | Feb |     |     |    | Mar |     |     |     |     | Apr |     |     |     | May |     |     |     |     | Jun |     |     |     |
|------|----------|-----|----|-----|-----|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|      | Week     | 1   | 2  | 3   | 4   | 5   | 6   | 7   | 8  | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | 19  | 20  | 21  | 22  | 23  | 24  | 25  | 26  |
| 2017 | Complete | 4   | 2  | 0   | 1   | 1   | 2   | 1   | 4  | 1   | 4   | 4   | 4   | 3   | 1   | 6   | 2   | 5   | 8   | 11  | 9   | 8   | 11  | 7   | 9   | 2   | 4   |
|      | Total    | 31  | 36 | 43  | 32  | 44  | 59  | 52  | 56 | 38  | 54  | 51  | 35  | 39  | 37  | 45  | 51  | 43  | 64  | 45  | 42  | 48  | 45  | 48  | 61  | 47  | 34  |
|      | Percent  | 13% | 6% | 0%  | 3%  | 2%  | 3%  | 2%  | 7% | 3%  | 7%  | 8%  | 11% | 8%  | 3%  | 13% | 4%  | 12% | 13% | 24% | 21% | 17% | 24% | 15% | 15% | 4%  | 12% |
| 2018 | Complete | 1   | 1  | 4   | 7   | 3   | 8   | 1   | 4  | 4   | 5   | 5   | 2   | 7   | 4   | 5   | 10  | 4   | 7   | 13  | 6   | 9   | 10  | 13  | 4   | 12  | 20  |
|      | Total    | 26  | 41 | 35  | 41  | 61  | 77  | 70  | 50 | 40  | 47  | 48  | 29  | 24  | 37  | 41  | 52  | 35  | 44  | 42  | 37  | 42  | 41  | 52  | 37  | 48  | 53  |
|      | Percent  | 4%  | 2% | 11% | 17% | 5%  | 10% | 1%  | 8% | 10% | 11% | 10% | 7%  | 29% | 11% | 12% | 19% | 11% | 16% | 31% | 16% | 21% | 24% | 25% | 11% | 25% | 38% |
| 2019 | Complete | 2   | 4  | 7   | 7   | 6   | 2   | 7   | 3  | 8   | 7   | 2   | 5   | 2   | 4   | 3   | 5   | 7   | 7   | 5   | 3   | 1   | 10  | 10  | 11  | 12  | 12  |
|      | Total    | 14  | 43 | 42  | 54  | 46  | 54  | 49  | 49 | 44  | 58  | 41  | 32  | 33  | 31  | 24  | 33  | 31  | 46  | 29  | 25  | 28  | 44  | 41  | 40  | 41  | 44  |
|      | Percent  | 14% | 9% | 17% | 13% | 13% | 4%  | 14% | 6% | 18% | 12% | 5%  | 16% | 6%  | 13% | 13% | 15% | 23% | 15% | 17% | 12% | 4%  | 23% | 24% | 28% | 29% | 27% |
| 2020 | Complete | 3   | 1  | 2   | 4   |     |     |     |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|      | Total    | 25  | 43 | 37  | 44  |     |     |     |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|      | Percent  | 12% | 2% | 5%  | 9%  |     |     |     |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

|      |          | Jul |     |     |     | Aug |     |     |     |     | Sep |    |     |     | Oct |    |    |     | Nov |    |     |     |     | Dec |    |     |     |
|------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|-----|----|----|-----|-----|----|-----|-----|-----|-----|----|-----|-----|
|      | Week     | 27  | 28  | 29  | 30  | 31  | 32  | 33  | 34  | 35  | 36  | 37 | 38  | 39  | 40  | 41 | 42 | 43  | 44  | 45 | 46  | 47  | 48  | 49  | 50 | 51  | 52  |
| 2017 | Complete | 10  | 7   | 12  | 24  | 10  | 13  | 5   | 4   | 4   | 6   | 3  | 5   | 3   | 0   | 1  | 2  | 4   | 2   | 0  | 4   | 3   | 1   | 4   | 3  | 5   | 2   |
|      | Total    | 36  | 56  | 57  | 88  | 63  | 57  | 40  | 45  | 47  | 44  | 33 | 60  | 55  | 42  | 37 | 38 | 39  | 32  | 37 | 34  | 39  | 49  | 48  | 61 | 45  | 23  |
|      | Percent  | 28% | 13% | 21% | 27% | 16% | 23% | 13% | 9%  | 9%  | 14% | 9% | 8%  | 5%  | 0%  | 3% | 5% | 10% | 6%  | 0% | 12% | 8%  | 2%  | 8%  | 5% | 11% | 9%  |
| 2018 | Complete | 8   | 12  | 14  | 16  | 31  | 18  | 6   | 6   | 9   | 5   | 2  | 6   | 9   | 10  | 3  | 3  | 2   | 5   | 4  | 4   | 8   | 4   | 5   | 2  | 1   | 3   |
|      | Total    | 28  | 38  | 58  | 65  | 81  | 64  | 25  | 33  | 36  | 31  | 35 | 42  | 48  | 49  | 49 | 32 | 26  | 39  | 44 | 36  | 28  | 28  | 50  | 37 | 37  | 15  |
|      | Percent  | 29% | 32% | 24% | 25% | 38% | 28% | 24% | 18% | 25% | 16% | 6% | 14% | 19% | 20% | 6% | 9% | 8%  | 13% | 9% | 11% | 29% | 14% | 10% | 5% | 3%  | 20% |
| 2019 | Complete | 13  | 5   | 19  | 16  | 22  | 21  | 3   | 6   | 5   | 2   | 4  | 2   | 8   | 3   | 0  | 2  | 1   | 2   | 3  | 1   | 7   | 12  | 6   | 1  | 8   | 0   |
|      | Total    | 38  | 39  | 61  | 51  | 59  | 73  | 30  | 40  | 44  | 30  | 43 | 23  | 39  | 33  | 22 | 27 | 33  | 31  | 36 | 38  | 49  | 29  | 29  | 38 | 45  | 16  |
|      | Percent  | 34% | 13% | 31% | 31% | 37% | 29% | 10% | 15% | 11% | 7%  | 9% | 9%  | 21% | 9%  | 0% | 7% | 3%  | 6%  | 8% | 3%  | 14% | 41% | 21% | 3% | 18% | 0%  |

Name: HPV Recommend-Well

4

**Description:** WELL visits with documented provider recommendation (given or refused) (% of visits with HPV due, ages 11-17)




|      |          | Jan |     |     |     | Feb |     |      |     | Mar |     |     |     |     | Apr |     |     |     | May |     |     |     |     | Jun |     |     |     |
|------|----------|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|      | Week     | 1   | 2   | 3   | 4   | 5   | 6   | 7    | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | 19  | 20  | 21  | 22  | 23  | 24  | 25  | 26  |
| 2017 | Complete | 4   | 2   | 0   | 1   | 0   | 1   | 1    | 2   | 1   | 4   | 3   | 4   | 3   | 1   | 6   | 2   | 4   | 8   | 8   | 5   | 8   | 9   | 6   | 9   | 2   | 4   |
|      | Total    | 10  | 6   | 10  | 5   | 5   | 6   | 3    | 11  | 6   | 12  | 8   | 13  | 10  | 8   | 15  | 17  | 14  | 24  | 14  | 16  | 29  | 27  | 21  | 24  | 22  | 18  |
|      | Percent  | 40% | 33% | 0%  | 20% | 0%  | 17% | 33%  | 18% | 17% | 33% | 38% | 31% | 30% | 13% | 40% | 12% | 29% | 33% | 57% | 31% | 28% | 33% | 29% | 38% | 9%  | 22% |
| 2018 | Complete | 1   | 1   | 3   | 6   | 4   | 7   | 1    | 4   | 4   | 5   | 2   | 1   | 5   | 4   | 5   | 9   | 3   | 6   | 12  | 5   | 9   | 11  | 12  | 6   | 13  | 20  |
|      | Total    | 9   | 5   | 8   | 9   | 9   | 9   | 1    | 7   | 8   | 7   | 12  | 5   | 11  | 10  | 7   | 12  | 10  | 11  | 18  | 11  | 16  | 28  | 26  | 15  | 28  | 41  |
|      | Percent  | 11% | 20% | 38% | 67% | 44% | 78% | 100% | 57% | 50% | 71% | 17% | 20% | 45% | 40% | 71% | 75% | 30% | 55% | 67% | 45% | 56% | 39% | 46% | 40% | 46% | 49% |
| 2019 | Complete | 1   | 2   | 6   | 6   | 5   | 2   | 7    | 6   | 8   | 7   | 1   | 5   | 2   | 3   | 3   | 5   | 6   | 6   | 4   | 3   | 2   | 10  | 11  | 13  | 9   | 14  |
|      | Total    | 3   | 7   | 10  | 12  | 10  | 7   | 8    | 8   | 10  | 10  | 4   | 11  | 7   | 4   | 6   | 9   | 8   | 11  | 7   | 5   | 11  | 20  | 21  | 22  | 17  | 26  |
|      | Percent  | 33% | 29% | 60% | 50% | 50% | 29% | 88%  | 75% | 80% | 70% | 25% | 45% | 29% | 75% | 50% | 56% | 75% | 55% | 57% | 60% | 18% | 50% | 52% | 59% | 53% | 54% |
| 2020 | Complete | 2   | 0   | 3   | 4   |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|      | Total    | 5   | 4   | 6   | 9   | ,   |     | •    |     |     |     |     |     |     |     | Ţ   |     | Ţ   | _   | _   | _   | _   |     |     |     |     |     |
|      | Percent  | 40% | 0%  | 50% | 44% |     |     |      |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

|      |          | Jul |     |     |     | Aug |     |     |     |     | Sep |     |     |     | Oct |     |     |     | Nov  |      |      |     |      | Dec |     |     |      |
|------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|-----|------|-----|-----|-----|------|
|      | Week     | 27  | 28  | 29  | 30  | 31  | 32  | 33  | 34  | 35  | 36  | 37  | 38  | 39  | 40  | 41  | 42  | 43  | 44   | 45   | 46   | 47  | 48   | 49  | 50  | 51  | 52   |
| 2017 | Complete | 10  | 6   | 11  | 23  | 9   | 13  | 5   | 3   | 3   | 6   | 3   | 4   | 3   | 0   | 1   | 2   | 4   | 2    | 0    | 3    | 2   | 1    | 1   | 3   | 5   | 2    |
|      | Total    | 24  | 27  | 33  | 52  | 34  | 29  | 15  | 15  | 17  | 15  | 10  | 18  | 13  | 7   | 12  | 7   | 6   | 5    | 4    | 10   | 14  | 6    | 9   | 6   | 8   | 6    |
|      | Percent  | 42% | 22% | 33% | 44% | 26% | 45% | 33% | 20% | 18% | 40% | 30% | 22% | 23% | 0%  | 8%  | 29% | 67% | 40%  | 0%   | 30%  | 14% | 17%  | 11% | 50% | 63% | 33%  |
| 2018 | Complete | 8   | 11  | 16  | 18  | 32  | 20  | 4   | 7   | 7   | 5   | 2   | 6   | 9   | 10  | 3   | 3   | 2   | 3    | 4    | 2    | 8   | 4    | 5   | 2   | 3   | 3    |
|      | Total    | 15  | 22  | 31  | 44  | 64  | 40  | 6   | 14  | 12  | 9   | 12  | 18  | 20  | 14  | 11  | 7   | 4   | 3    | 7    | 2    | 12  | 4    | 10  | 6   | 5   | 3    |
|      | Percent  | 53% | 50% | 52% | 41% | 50% | 50% | 67% | 50% | 58% | 56% | 17% | 33% | 45% | 71% | 27% | 43% | 50% | 100% | 57%  | 100% | 67% | 100% | 50% | 33% | 60% | 100% |
| 2019 | Complete | 16  | 7   | 18  | 19  | 21  | 21  | 3   | 5   | 4   | 2   | 4   | 2   | 7   | 3   | 0   | 2   | 1   | 2    | 3    | 1    | 9   | 12   | 6   | 1   | 10  | 0    |
|      | Total    | 25  | 15  | 36  | 34  | 28  | 46  | 6   | 12  | 12  | 3   | 9   | 6   | 13  | 11  | 2   | 10  | 6   | 9    | 3    | 3    | 10  | 19   | 11  | 3   | 15  | 1    |
|      | Percent  | 64% | 47% | 50% | 56% | 75% | 46% | 50% | 42% | 33% | 67% | 44% | 33% | 54% | 27% | 0%  | 20% | 17% | 22%  | 100% | 33%  | 90% | 63%  | 55% | 33% | 67% | 0%   |

Name: HPV Recommend-All

**Description:** ALL visits with documented provider recommendation (given or refused) (% of visits with HPV due, ages 11-17)




|      |          | Jan |    |     |     | Feb |     |     |     | Mar |     |     |     |     | Apr |     |     |     | May |     |     |     |     | Jun |     |     |     |
|------|----------|-----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|      | Week     | 1   | 2  | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | 19  | 20  | 21  | 22  | 23  | 24  | 25  | 26  |
| 2017 | Complete | 4   | 2  | 0   | 1   | 1   | 2   | 1   | 4   | 1   | 4   | 4   | 4   | 3   | 1   | 6   | 2   | 5   | 8   | 11  | 9   | 8   | 11  | 7   | 9   | 2   | 4   |
|      | Total    | 31  | 36 | 43  | 32  | 44  | 59  | 52  | 56  | 38  | 54  | 51  | 35  | 39  | 37  | 45  | 51  | 43  | 64  | 45  | 42  | 48  | 45  | 48  | 61  | 47  | 34  |
|      | Percent  | 13% | 6% | 0%  | 3%  | 2%  | 3%  | 2%  | 7%  | 3%  | 7%  | 8%  | 11% | 8%  | 3%  | 13% | 4%  | 12% | 13% | 24% | 21% | 17% | 24% | 15% | 15% | 4%  | 12% |
| 2018 | Complete | 1   | 1  | 4   | 7   | 4   | 8   | 1   | 5   | 4   | 5   | 5   | 2   | 7   | 5   | 5   | 10  | 4   | 7   | 13  | 6   | 9   | 11  | 13  | 6   | 13  | 22  |
|      | Total    | 26  | 41 | 35  | 41  | 61  | 77  | 70  | 50  | 40  | 47  | 48  | 29  | 24  | 37  | 41  | 52  | 35  | 44  | 42  | 37  | 42  | 41  | 52  | 37  | 48  | 53  |
|      | Percent  | 4%  | 2% | 11% | 17% | 7%  | 10% | 1%  | 10% | 10% | 11% | 10% | 7%  | 29% | 14% | 12% | 19% | 11% | 16% | 31% | 16% | 21% | 27% | 25% | 16% | 27% | 42% |
| 2019 | Complete | 2   | 4  | 8   | 7   | 6   | 2   | 8   | 7   | 9   | 10  | 2   | 5   | 2   | 4   | 4   | 5   | 7   | 7   | 5   | 3   | 2   | 10  | 12  | 15  | 12  | 14  |
|      | Total    | 14  | 43 | 42  | 54  | 46  | 54  | 49  | 49  | 44  | 58  | 41  | 32  | 33  | 31  | 24  | 33  | 31  | 46  | 29  | 25  | 28  | 44  | 41  | 40  | 41  | 44  |
|      | Percent  | 14% | 9% | 19% | 13% | 13% | 4%  | 16% | 14% | 20% | 17% | 5%  | 16% | 6%  | 13% | 17% | 15% | 23% | 15% | 17% | 12% | 7%  | 23% | 29% | 38% | 29% | 32% |
| 2020 | Complete | 3   | 1  | 3   | 4   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|      | Total    | 25  | 43 | 37  | 44  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|      | Percent  | 12% | 2% | 8%  | 9%  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

|      |          | Jul |     |     |     | Aug |     |     |     |     | Sep |     |     |     | Oct |    |    |     | Nov |     |     |     |     | Dec |    |     |     |
|------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|----|----|-----|-----|-----|-----|-----|-----|-----|----|-----|-----|
|      | Week     | 27  | 28  | 29  | 30  | 31  | 32  | 33  | 34  | 35  | 36  | 37  | 38  | 39  | 40  | 41 | 42 | 43  | 44  | 45  | 46  | 47  | 48  | 49  | 50 | 51  | 52  |
| 2017 | Complete | 10  | 7   | 12  | 24  | 10  | 13  | 5   | 4   | 4   | 6   | 3   | 5   | 3   | 0   | 1  | 2  | 4   | 2   | 0   | 4   | 3   | 1   | 4   | 3  | 5   | 2   |
|      | Total    | 36  | 56  | 57  | 88  | 63  | 57  | 40  | 45  | 47  | 44  | 33  | 60  | 55  | 42  | 37 | 38 | 39  | 32  | 37  | 34  | 39  | 49  | 48  | 61 | 45  | 23  |
|      | Percent  | 28% | 13% | 21% | 27% | 16% | 23% | 13% | 9%  | 9%  | 14% | 9%  | 8%  | 5%  | 0%  | 3% | 5% | 10% | 6%  | 0%  | 12% | 8%  | 2%  | 8%  | 5% | 11% | 9%  |
| 2018 | Complete | 8   | 12  | 16  | 19  | 33  | 21  | 7   | 7   | 9   | 5   | 2   | 6   | 9   | 10  | 3  | 3  | 2   | 5   | 5   | 4   | 9   | 4   | 5   | 3  | 3   | 4   |
|      | Total    | 28  | 38  | 58  | 65  | 81  | 64  | 25  | 33  | 36  | 31  | 35  | 42  | 48  | 49  | 49 | 32 | 26  | 39  | 44  | 36  | 28  | 28  | 50  | 37 | 37  | 15  |
|      | Percent  | 29% | 32% | 28% | 29% | 41% | 33% | 28% | 21% | 25% | 16% | 6%  | 14% | 19% | 20% | 6% | 9% | 8%  | 13% | 11% | 11% | 32% | 14% | 10% | 8% | 8%  | 27% |
| 2019 | Complete | 16  | 7   | 20  | 20  | 24  | 21  | 3   | 6   | 5   | 2   | 5   | 2   | 8   | 3   | 0  | 2  | 1   | 2   | 3   | 1   | 9   | 12  | 6   | 1  | 10  | 0   |
|      | Total    | 38  | 39  | 61  | 51  | 59  | 73  | 30  | 40  | 44  | 30  | 43  | 23  | 39  | 33  | 22 | 27 | 33  | 31  | 36  | 38  | 49  | 29  | 29  | 38 | 45  | 16  |
|      | Percent  | 42% | 18% | 33% | 39% | 41% | 29% | 10% | 15% | 11% | 7%  | 12% | 9%  | 21% | 9%  | 0% | 7% | 3%  | 6%  | 8%  | 3%  | 18% | 41% | 21% | 3% | 22% | 0%  |

Name: Bundle Adol Vax

**Description:** Visits for ages 11-12 year-olds in which HPV & meningococcal vaccines are bundled with

Tdap, when due (% of visits, ages 11-12)



|      |          | Jan    | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct  | Nov  | Dec |
|------|----------|--------|-----|-----|-----|-----|-----|-----|-----|-----|------|------|-----|
| 2017 | Complete | 0      | 0   | 0   | 1   | 0   | 0   | 0   | 0   | 0   | 0    | 1    | 0   |
|      | Total    | 0      | 0   | 2   | 2   | 0   | 2   | 3   | 3   | 0   | 0    | 1    | 0   |
|      | Percent  | 0%     | 0%  | 0%  | 50% | 0%  | 0%  | 0%  | 0%  | 0%  | 0%   | 100% | 0%  |
| 2018 | Complete | 3      | 1   | 4   | 4   | 4   | 8   | 5   | 10  | 1   | 4    | 10   | 1   |
|      | Total    | 3      | 2   | 6   | 5   | 5   | 12  | 8   | 16  | 2   | 4    | 12   | 2   |
|      | Percent  | 100%   | 50% | 67% | 80% | 80% | 67% | 63% | 63% | 50% | 100% | 83%  | 50% |
| 2019 | Complete | 4      | 4   | 11  | 6   | 4   | 9   | 15  | 17  | 3   | 0    | 6    | 4   |
|      | Total    | 4      | 5   | 14  | 8   | 7   | 19  | 28  | 22  | 4   | 3    | 8    | 6   |
|      | Percent  | 100%   | 80% | 79% | 75% | 57% | 47% | 54% | 77% | 75% | 0%   | 75%  | 67% |
| 2020 | Complete | 1      |     |     |     |     |     |     |     |     |      |      |     |
|      | Total    | 5      |     |     |     |     |     |     |     |     |      |      |     |
|      | Percent  | 20.00% |     |     |     |     |     |     |     |     |      |      |     |